

Adrian G Mcnicholl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3115465/publications.pdf>

Version: 2024-02-01

56
papers

2,453
citations

257357

24
h-index

197736

49
g-index

59
all docs

59
docs citations

59
times ranked

2540
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 613-623. | 1.9 | 266 |
| 2 | Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1190-1198. | 0.9 | 265 |
| 3 | Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2009, 41, 56-66. | 0.4 | 195 |
| 4 | Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 126-137. | 1.9 | 186 |
| 5 | Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 414-425. | 1.9 | 165 |
| 6 | Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice. <i>Gut</i> , 2014, 63, 244-249. | 6.1 | 119 |
| 7 | Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1485-1491. | 0.9 | 114 |
| 8 | Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1746-1754. | 0.9 | 97 |
| 9 | IV Conferencia Española de Consenso sobre el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología Y Hepatología</i> , 2016, 39, 697-721. | 0.2 | 97 |
| 10 | <i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 768-775. | 1.9 | 91 |
| 11 | A review of rescue regimens after clarithromycin-containing triple therapy failure (for <i>Helicobacter</i>) <i>Tj ETQq1 1 0.784314 rgBT/Overlook</i> | 0.9 | 73 |
| 12 | Optimization strategies aimed to increase the efficacy of <i>H. pylori</i> eradication therapies. <i>Helicobacter</i> , 2017, 22, e12392. | 1.6 | 69 |
| 13 | Combination of Bismuth and Standard Triple Therapy Eradicates <i>Helicobacter pylori</i> Infection in More than 90% of Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 89-98. | 2.4 | 62 |
| 14 | Meta-analysis of three single capsule bismuth-containing quadruple therapy for the eradication of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 2019, 24, e12570. | 1.6 | 57 |
| 15 | Accuracy of GastroPanel for the diagnosis of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 941-948. | 0.8 | 54 |
| 16 | Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for <i>H. pylori</i> Infection. <i>Digestive Diseases and Sciences</i> , 2014, 59, 383-389. | 1.1 | 48 |
| 17 | Protocol of the European Registry on the management of <i>Helicobacter pylori</i> infection (HpEuReg). <i>Helicobacter</i> , 2019, 24, e12630. | 1.6 | 46 |
| 18 | <i>Helicobacter Pylori</i> First-Line and Rescue Treatments in the Presence of Penicillin Allergy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 458-464. | 1.1 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. The Cochrane Library, 2016, , CD009034. | 1.5 | 35 |
| 20 | Probiotic supplementation with <i>Lactobacillus plantarum</i> and <i>Pediococcus acidilactici</i> for <i>Helicobacter pylori</i> therapy: A randomized, double-blind, placebo-controlled trial. <i>Helicobacter</i> , 2018, 23, e12529. | 1.6 | 34 |
| 21 | Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple or concomitant treatment to eradicate <i>H. pylori</i> infection. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 652-656. | 0.6 | 32 |
| 22 | IV Spanish Consensus Conference on <i>Helicobacter pylori</i> infection treatment. <i>Gastroenterología y Hepatología</i> (English Edition), 2016, 39, 697-721. | 0.0 | 27 |
| 23 | Methotrexate in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1086-1091. | 0.8 | 26 |
| 24 | Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for <i>Helicobacter pylori</i> Eradication: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 765-776. | 4.9 | 23 |
| 25 | Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. <i>Digestive and Liver Disease</i> , 2015, 47, 108-113. | 0.4 | 22 |
| 26 | Spanish primary care survey on the management of <i>Helicobacter pylori</i> infection and dyspepsia: Information, attitudes, and decisions. <i>Helicobacter</i> , 2019, 24, e12593. | 1.6 | 18 |
| 27 | <i>Helicobacter pylori</i> inactivation and virulence gene damage using a supported sensitizer for photodynamic therapy. <i>European Journal of Medicinal Chemistry</i> , 2013, 68, 284-290. | 2.6 | 17 |
| 28 | Research to the N-Power: The Strengths of Networked Clinical Collaboration in Spain. <i>American Journal of Gastroenterology</i> , 2017, 112, 1761-1764. | 0.2 | 16 |
| 29 | Maintenance of <i>Helicobacter pylori</i> Eradication Rates with Triple Therapy Over 12 Years in a Spanish hospital. <i>Helicobacter</i> , 2012, 17, 160-161. | 1.6 | 12 |
| 30 | Empirical <i>Helicobacter pylori</i> rescue therapy: an 18-year single-centre study of 1200 patients. <i>GastroHep</i> , 2019, 1, 311-324. | 0.3 | 12 |
| 31 | Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin) Tj ETQq1 1 0.784314 rgBT /Overl Hepatología, 2017, 40, 658-662. | 0.2 | 11 |
| 32 | <i>Helicobacter pylori</i> treatment results in Slovenia in the period 2013-2015 as a part of European Registry on <i>Helicobacter pylori</i> Management. <i>Radiology and Oncology</i> , 2017, 52, 1-6. | 0.6 | 9 |
| 33 | Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq1 1 0.784314 rgBT /Overl Gastroenterología y Hepatología, 2020, 43, 117-125. | 0.2 | 6 |
| 34 | Su1171 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple or Concomitant Treatment to Eradicate <i>H. pylori</i> Infection. <i>Gastroenterology</i> , 2014, 146, S-394. | 0.6 | 5 |
| 35 | A quick flow cytometry protocol to assess <i>Helicobacter pylori</i> viability. <i>Journal of Microbiological Methods</i> , 2020, 177, 106043. | 0.7 | 5 |
| 36 | Alertas sobre la seguridad de las quinolonas: ¿debemos modificar su prescripción en el tratamiento de la infección por <i>Helicobacter pylori</i> . <i>Gastroenterología y Hepatología</i> , 2019, 42, 461-463. | 0.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Meta-Analysis: Rabeprazole and Esomeprazole in the Eradication of Helicobacter pylori. Gastroenterology, 2011, 140, S-880. | 0.6 | 2 |
| 38 | Amoxicillin Gastric Retention Systems for Helicobacter pylori Treatment. Gastroenterology, 2011, 140, S-880. | 0.6 | 2 |
| 39 | S1186 The Diagnostic Accuracy of Faecal Calprotectin in Inflammatory Bowel Disease (IBD): A Systematic Review. Gastroenterology, 2008, 134, A-196-A-197. | 0.6 | 1 |
| 40 | M1055 Accuracy of GastroPanel for Non Invasive Diagnosis of Atrophic Gastritis. Gastroenterology, 2009, 136, A-340. | 0.6 | 1 |
| 41 | M1697 Effect of Helicobacter pylori Eradication on Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Randomized Clinical Trials. Gastroenterology, 2010, 138, S-400. | 0.6 | 1 |
| 42 | M1698 Helicobacter pylori and Iron-Deficiency Anaemia (IDA): A Meta-Analysis of Case-Control Studies. Gastroenterology, 2010, 138, S-401. | 0.6 | 1 |
| 43 | Sa1916 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple Sequential or Concomitant Treatment to Eradicate H. pylori Infection. Gastroenterology, 2013, 144, S-334. | 0.6 | 1 |
| 44 | Optimum second-line regimens for Helicobacter pylori eradication. The Cochrane Library, 2014, , . | 1.5 | 1 |
| 45 | Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 104-105. | 0.8 | 1 |
| 46 | Response to. European Journal of Gastroenterology and Hepatology, 2015, 27, 105-106. | 0.8 | 1 |
| 47 | In <i>H. pylori</i> -infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal. Evidence-Based Medicine, 2016, 21, 144-144. | 0.6 | 1 |
| 48 | Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2822-2823. | 2.4 | 1 |
| 49 | S1185 Faecal Calprotectin's Utility in the Prediction of Inflammatory Bowel Disease (IBD) Relapses. Gastroenterology, 2008, 134, A-196. | 0.6 | 0 |
| 50 | M1095 Empirical Rescue Therapy After H. pylori Treatment Failure: A 10-Year Single Center Study of 500 Patients. Gastroenterology, 2008, 134, A-337. | 0.6 | 0 |
| 51 | Meta-Analysis of Levofloxacin-Containing Triple Therapy vs. Bismuth-Containing Quadruple Therapy as Second-Line Treatment in the Eradication of Helicobacter pylori. Gastroenterology, 2011, 140, S-880. | 0.6 | 0 |
| 52 | Sa1891 Helicobacter pylori Activates CD277, a New Co-Inhibitory Molecule. Gastroenterology, 2013, 144, S-328. | 0.6 | 0 |
| 53 | Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy. European Journal of Internal Medicine, 2016, 33, 1-2. | 1.0 | 0 |
| 54 | Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?. Gastroenterology and Hepatology (English Edition), 2019, 42, 461-463. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq1 1 0.784314 rgBT /Overlook GastroenterologÃa Y HepatologÃa (English Edition), 2020, 43, 117-125. | 0.0 | 0 |
| 56 | Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. GastroenterologÃa Y HepatologÃa, 2020, 43, 79-86. | 0.2 | 0 |